Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2016 - 2025)

Lineage Cell Therapeutics' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $186000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 23.18% year-over-year to $186000.0; the TTM value through Dec 2025 reached $699000.0, up 19.08%, while the annual FY2025 figure was $699000.0, 19.08% up from the prior year.
  • Depreciation & Amortization (CF) reached $186000.0 in Q4 2025 per LCTX's latest filing, up from $178000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $186000.0 in Q4 2025 to a low of $138000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $154650.0, with a median of $150500.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 21.9% in 2021, then rose 26.24% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $159000.0 in 2021, then fell by 11.32% to $141000.0 in 2022, then grew by 1.42% to $143000.0 in 2023, then rose by 5.59% to $151000.0 in 2024, then grew by 23.18% to $186000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Depreciation & Amortization (CF) are $186000.0 (Q4 2025), $178000.0 (Q3 2025), and $171000.0 (Q2 2025).